Compounded semaglutide and tirzepatide: what's real, what's hype
Quick answer
The creator references personal use of compounded semaglutide or tirzepatide at a self-described peak of '80 units,' a measurement not used in any FDA-approved dosing protocol for either drug. Without confirmed vial concentration, this figure cannot be interpreted as a safe or meaningful dose reference. Compounded GLP-1 products are not FDA-approved and have been subject to FDA safety alerts regarding dosing errors and product quality since 2023.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @haleighweaver5 actually say?
The claim here is brief but carries weight. The creator says she had "gone up to like 80 units at one point" of what the video caption identifies as compounded semaglutide or tirzepatide, and frames this as her personal high-water mark. She's not giving a tutorial, but the context, a reply about affordable compounded GLP-1s for weight loss, makes this a dosing reference that viewers will treat as informational.
The problem is that "units" is not the standard measurement for semaglutide or tirzepatide dosing. These drugs are typically measured in milligrams. Insulin is measured in units. This distinction is not trivial. Confusing the two measurement systems in the context of injectable medications is exactly the kind of slip that has contributed to serious medication errors in real clinical settings.
Does the science back this up?
There is no published clinical protocol for semaglutide or tirzepatide dosed in "units." This is not a minor terminology quibble. The FDA-approved dosing for semaglutide (Wegovy) tops out at 2.4 mg weekly. Tirzepatide (Zepbound) reaches a maximum of 15 mg weekly. Neither drug is expressed in units in any manufacturer labeling or peer-reviewed literature.
The confusion may stem from how some compounding pharmacies package these drugs. Compounded semaglutide is often supplied in vials where patients self-administer using insulin syringes, which are calibrated in units. A patient drawing 80 units on an insulin syringe could be drawing anywhere from 0.8 mg to several milligrams depending on the vial concentration. Concentration varies between compounding pharmacies and is not standardized. Bhatt et al. (2022, NEJM) and the broader STEP trial series established efficacy and safety at specific mg doses, none of which were described in units.
What did they get wrong (or right)?
The creator gets credit for one thing: she signals this was her personal experience and frames it as a past dosing level she has moved away from. That's honest. She's not telling viewers to dose at 80 units.
What she gets wrong, or at least dangerously imprecise about, is using "units" without any clarification of vial concentration. Without knowing the concentration of the compounded vial, 80 units is a meaningless number. It could represent a safe dose or a dangerous one. The Institute for Safe Medication Practices has flagged unit-based confusion with non-insulin injectables as a recurring source of overdose risk. A 2023 FDA safety communication specifically warned about dosing errors with compounded semaglutide products tied to concentration misunderstandings. Repeating this framing to 34,800 viewers, without clarification, is a problem regardless of intent.
What should you actually know?
If you are using or considering compounded semaglutide or tirzepatide, the measurement system matters more than the number. Always confirm the concentration of your compounded vial in mg per mL with your prescribing clinician before drawing any dose. A dose described only in "units" without a known concentration is not a safe reference point.
Compounded GLP-1 medications are not FDA-approved and are not equivalent to brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. They may be legal to prescribe under shortage provisions, but they have not undergone the same manufacturing and efficacy review. The FDA has issued multiple warnings about compounded semaglutide quality since 2023. If your provider or an online source is describing your GLP-1 dose in units without specifying concentration, that is a red flag worth raising before your next injection.
- Always verify the mg/mL concentration of any compounded GLP-1 vial with a licensed prescriber.
- Dosing errors with compounded injectables have been reported to the FDA. Report adverse events at MedWatch.
- "Affordable" compounded GLP-1s vary widely in quality, concentration, and regulatory oversight.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Compounded semaglutide and tirzepatide: what's real, what's hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator references personal use of compounded semaglutide or tirzepatide at a self-described peak of '80 units,' a measurement not used in any FDA-approved dosing protocol for either drug.
FormBlends verdict
The creator references personal use of compounded semaglutide or tirzepatide at a self-described peak of '80 units,' a measurement not used in any FDA-approved dosing protocol for either drug. Without confirmed vial concentration, this figure cannot be interpreted as a safe or meaningful dose reference. Compounded GLP-1 products are not FDA-approved and have been subject to FDA safety alerts regarding dosing errors and product quality since 2023.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator references personal use of compounded semaglutide or tirzepatide at a self-described peak of '80 units,' a measurement not used in any FDA-approved dosing protocol for either drug. Without confirmed vial concentration, this figure cannot be interpreted as a safe or meaningful dose reference. Compounded GLP-1 products are not FDA-approved and have been subject to FDA safety alerts regarding dosing errors and product quality since 2023.
- Semaglutide and tirzepatide are dosed in milligrams, not units. The FDA has never approved a unit-based dosing protocol for either drug.
- The FDA issued a 2023 safety communication warning that compounded semaglutide dosing errors are frequently tied to concentration confusion when patients use insulin syringes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Semaglutide and tirzepatide are dosed in milligrams, not units. The FDA has never approved a unit-based dosing protocol for either drug.
- The FDA issued a 2023 safety communication warning that compounded semaglutide dosing errors are frequently tied to concentration confusion when patients use insulin syringes.
- STEP 1 trial data (Wilding et al., 2021, NEJM) established semaglutide efficacy at 2.4 mg weekly. This data does not apply to compounded formulations with unverified concentrations.
- Compounded GLP-1 medications are not equivalent to brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. They are permitted under shortage provisions but have not passed the same FDA manufacturing review.
- The Institute for Safe Medication Practices has documented overdose cases linked to unit-based confusion with non-insulin injectable medications.
- Always confirm the mg/mL concentration of any compounded GLP-1 vial directly with a licensed prescriber before drawing or administering a dose.
- 34,800 viewers encountering an uncontextualized '80 units' reference without concentration data represents a genuine patient safety communication risk.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Haleigh | Wellness & Lifestyle · TikTok creator
34.8K views on this video
Replying to @Kate Affordable compounded Semaglutide/Trizepatide for Weightloss!! #semaglutide #weightlosstransformation #tirzepatide #fatlosstips #semaglutideforweightloss #fatlosstransformations #tirzepatideweightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Haleigh | Wellness & Lifestyle, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.